Abstract:DADA2 deficiency caused by new homozygous variation in 22q11.1Sir, Adenosine deaminase 2 (DADA2) deficiency is a monogenic auto-inflammatory syndrome first described in 2014.It is characterised by a polyarteritis nodosa-like vasculopathy with livedo reticularis, skin ulcers, subcutaneous rashes, aphthous ulcers, and leukocytoclastic vasculitis, as well as early-onset neurological symptoms such as stroke and polyneuropathy.Although the exact incidence of DADA2 is unknown, it can be as high as 4 per 100,000.Two of the most common pathogenic variants of DADA2 are p.G47R and p.R169Q.Recent studies have revealed that mutations in cat eye chromosome region 1 (CECR1) gene, which encodes a defect in DADA2, are associated with vascular inflammatory lesions such as polyarteritis nodosa.Here, we report a 16-year-old adolescent followed up as having Raynaud's phenomenon, with green reticular spots of the lower limbs for many years.The patient was lymphopenic and had low serum immunoglobulin A levels.Laboratory tests showed anaemia, severe neutropenia, lymphopenia, moderately elevated erythrocyte sedimentation rate, and a positive C-reactive protein level.ANA and ANCA were not detected.Anti-ds-DNA and aPL antibodies were normal.CTA of the entire aorta showed multiple small aneurysms in branches that were less than grade 3 of the intra-abdominal arteries (Fig. 1).Furthermore, computed tomography scans of the brain, chest, and abdomen showed no abnormal enlargement of lymph nodes or solid masses.Given his Raynaud's phenomenon, reticular green spots, and small aneurysms, we performed genetic analysis of mutations in the DADA2 gene.Whole-exome sequencing revealed a homozygous mutation: c.97(exonl)_c98(exonl)insA (Fig. 2).No DADA2 mutations were detected in his parents' DNA.Our patient had significantly lower 0.5 and 1 h DADA2 enzyme activity compared with the control and his father's samples, suggesting that our patient had DADA2 enzyme deficiency (Fig. 3).In this case, the symptoms of an inflammatory reaction were consistent with the diagnosis of DADA2, ultimately leading to the initiation of appropriate DADA2 treatment.We started treatment with methylprednisolone (40 mg per day).After one month of treatment, we started to reduce the dose of methylprednisolone due to decreased in ESR and CRP.We were able to reduce the methylprednisolone dosage to 32 mg per day and added 20 mg of leflunomide per day.The ESR and CRP decreased to normal.The methylprednisolone dose of 32 mg was changed to oral hormone, and cyclophosphamide was successively given,

A case report on deficiency of adenosine deaminase 2 with relapse–remission course and analysis of genotype–phenotype correlation

Genotype and Functional Correlates of Disease Phenotype in Deficiency of Adenosine Deaminase 2 (DADA2).

A Cohort Study on Deficiency of ADA2 from China

Deficiency of Adenosine Deaminase 2 in Adult Siblings: Many Years of a Misdiagnosed Disease with Severe Consequences

Deficiency of Adenosine Deaminase 2 (DADA2): Hidden Variants, Reduced Penetrance, and Unusual Inheritance

DADA2 Deficiency Caused by New Homozygous Variation in 22Q11.1

Deficiency of adenosine deaminase 2 (DADA2) with bilateral renal subcapsular hematoma: a case report and literature review

Delayed-onset Adenosine Deaminase Deficiency with a Novel Synonymous Mutation and a Case Series from China

Comparison of disease phenotypes and mechanistic insight on causal variants in patients with DADA2

Case Report: Deficiency of Adenosine Deaminase 2 Presenting With Overlapping Features of Autoimmune Lymphoproliferative Syndrome and Bone Marrow Failure

Early bone marrow alterations in patients with adenosine deaminase 2 deficiency across disease phenotypes and severities

Deficiency of Adenosine Deaminase 2 in Adults and Children: Experience From India

Adenosine Deaminase 2 Deficiency (DADA2): A Crosstalk Between Innate and Adaptive Immunity

Genotype and Phenotype of Adenosine Deaminase 2 Deficiency: a Report from Saudi Arabia

Disrupted N-linked Glycosylation As a Disease Mechanism in Deficiency of ADA2.

Clinical Symptoms, Laboratory Parameters and Long-Term Follow-up in a National DADA2 Cohort

Carrier Frequency and Incidence Estimation of Deficiency of Adenosine Deaminase 2 in the Chinese Population Based on Massive Exome Sequencing Data

Deficiency of Adenosine Deaminase 2

Human ADA2 Deficiency: Ten Years Later

Evaluation and Management of Deficiency of Adenosine Deaminase 2: an International Consensus Statement.

Deficiency of Adenosine Deaminase 2 Causes Antibody Deficiency